Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 09.02.2026 1 Ann Thorac Surg 7 Anticancer Res 2 BMC Cancer 1 Br J Cancer 1 Cancer 1 Cancer Res 2 Cancer Sci 2 Clin Nucl Med 1 Eur J Cancer 2 Eur J Cardiothorac Surg 1 Hum Pathol 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 2 J Clin Invest 3 J Clin Oncol 1 J Surg Oncol 1 J Thorac Cardiovasc Surg 9 J Thorac Oncol 1 Lancet Oncol 1 Lung Cancer 1 Nat Med 1 Oncogene 2 Oncol Rep 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Thorac Surg

1. MUBASHIR M
   Robotic versus Video-Assisted Thoracoscopic Surgery in Non-Small Cell Lung Cancer After Neoadjuvant Therapy: which is superior?!
   Ann Thorac Surg. 2026 Jan 29:S0003-4975(26)00087.
   PubMed        
   
   

   
   Anticancer Res

2. YAMAGUCHI Y, Yoshida T, Higashiyama RI, Masuda K, et al
   Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.
   Anticancer Res. 2026;46:1067-1077.
   PubMed         Abstract available
   
   
3. HUNG HY, Lee TH, Chuang CH, Lee MH, et al
   First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.
   Anticancer Res. 2026;46:917-938.
   PubMed         Abstract available
   
   
4. CHECK JH, Check DL, Ganpo-Nkewnkwa N
   Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone.
   Anticancer Res. 2026;46:1153-1165.
   PubMed         Abstract available
   
   
5. UCHIYAMA T, Asanuma K, Kita K, Okamoto T, et al
   Amlodipine Suppresses Lung Metastasis by Increasing Cell Stiffness.
   Anticancer Res. 2026;46:689-703.
   PubMed         Abstract available
   
   
6. OKADO S, Nakamura S, Sugihara M, Kinoshita F, et al
   Prognostic Factors for Pulmonary Metastasectomy for Colorectal Cancer: A Propensity Score Matching Analysis.
   Anticancer Res. 2026;46:1143-1152.
   PubMed         Abstract available
   
   
7. TSUKIOKA T, Nakajima R, Chung K, Okada S, et al
   Tumor Location Significantly Correlates With PD-L1 Status in Patients With Small Sized Non-small Cell Lung Cancer.
   Anticancer Res. 2026;46:911-916.
   PubMed         Abstract available
   
   
8. SHEN YW, Lee TH, Hung HY, Liu YW, et al
   Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer.
   Anticancer Res. 2026;46:1001-1020.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. MIYAMOTO I, Shimizu T, Hanamura M, Tanaka R, et al
   Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study.
   BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15646.
   PubMed         Abstract available
   
   
10. LIUFU Y, Su R, Wen Y, Guan Y, et al
    A CT-based deep learning approach to differentiate multiple primary lung cancers, metastases, and benign nodules.
    BMC Cancer. 2026;26:177.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. TSUCHIDA S, Taki T, Nomura K, Suzuki K, et al
    Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness.
    Br J Cancer. 2026;134:567-576.
    PubMed         Abstract available
    
    

    
    Cancer

12. LEVI FA
    Early time of day of administration of immunochemotherapy for enhancing overall survival in patients with lung cancer irrespective of histological type?
    Cancer. 2026;132:e70290.
    PubMed        
    
    

    
    Cancer Res

13. JUNTTILA MR, Repellin CE, Salaniwal S, Warne R, et al
    Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.
    Cancer Res. 2026;86:759-772.
    PubMed         Abstract available
    
    

    
    Cancer Sci

14. LUO X, Xu J, Wang Z, Wang X, et al
    Spatial Location of SPP1(+)TAMs and Mutually Exclusive Subsets Based on Single-Cell and Transcriptome Data.
    Cancer Sci. 2026;117:548-565.
    PubMed         Abstract available
    
    
15. KONO K, Tanino R, Tsubata Y, Haque EF, et al
    Microtubule Inhibitors Induce Cross-Resistance to Osimertinib Through CaMKII Activation in EGFR-Mutated NSCLC.
    Cancer Sci. 2026;117:418-428.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

16. ATTASETH P, Zhuang H
    Pleuropulmonary Blastoma on FDG PET/CT in a Pediatric Patient Before and After Treatment.
    Clin Nucl Med. 2025 May 13. doi: 10.1097/RLU.0000000000005958.
    PubMed         Abstract available
    
    
17. LIU X, Zhao Y, Tian C, Wang W, et al
    A case of sarcomatoid carcinoma of the lung treated with a new radiopharmaceutical 225Ac-DOTA-IBA.
    Clin Nucl Med. 2026;51:268-270.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

18. ALTHOFF FC, Hummel HD, Kokowski K, Elender C, et al
    Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).
    Eur J Cancer. 2026;236:116265.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

19. LA PAGLIA D, Ciacco C, Grispi C, Rudella S, et al
    Is Ventilatory Equivalent for Carbon Dioxide (VE/VCO2) Slope the Key to Reduce Mortality in Patients Undergoing Pneumonectomy?
    Eur J Cardiothorac Surg. 2026;68:ezag040.
    PubMed         Abstract available
    
    
20. LU L, Shuhuan Y, Zuyuan Z, Xiang S, et al
    Effects of two rehabilitation protocols on pulmonary function in lung cancer patients after thoracoscopic surgery: A randomized controlled trial of baduanjin versus bedside cycle ergometer training.
    Eur J Cardiothorac Surg. 2026 Feb 3:ezag071. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Hum Pathol

21. JIANG P, Chen W, Song X, Li X, et al
    Deep learning-based classification of lung adenocarcinoma subtypes in histopathological images using DS-EffNet.
    Hum Pathol. 2026;168:106020.
    PubMed         Abstract available
    
    

    
    Int J Cancer

22. MOU B, Duan Y, Wang J, Li T, et al
    Genomic signature driving preinvasive to invasive processes in stage I lung adenocarcinoma.
    Int J Cancer. 2026;158:1975-1988.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

23. LIN CS, Shen C, Banks T, Prasad R, et al
    Feasibility, Workflow, Dosimetry and PET Signal Trends in Lung Cancer Treated with Biology-Guided Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2026 Feb 4:S0360-3016(25)06621.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

24. BRANDT VP, Sander C, Holland L, Koschny R, et al
    High resolution genome-wide SNP array analyses on matched colorectal-based lung and brain metastases.
    J Cancer Res Clin Oncol. 2026;152:47.
    PubMed         Abstract available
    
    

    
    J Clin Invest

25. GHOSH M, Wu C, Kumar A, Nilsson M, et al
    Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression.
    J Clin Invest. 2025;136:e198418.
    PubMed         Abstract available
    
    
26. LI H, De Santis MC, Tucci FA, Tosoni D, et al
    SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
    J Clin Invest. 2026;136:e192705.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

27. REUSS JE, Bazhenova L, Ismaila N, Abu Rous F, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.
    J Clin Oncol. 2026 Feb 3:JCO2502825. doi: 10.1200/JCO-25-02825.
    PubMed         Abstract available
    
    
28. PURI S, Leighl NB, Ismaila N, Rous FA, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.
    J Clin Oncol. 2026 Feb 3:JCO2502822. doi: 10.1200/JCO-25-02822.
    PubMed         Abstract available
    
    
29. REMON J, Cascone T, Peters S
    Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Feb 6:JCO2600221. doi: 10.1200/JCO-26-00221.
    PubMed        
    
    

    
    J Surg Oncol

30. NAKABACHI K, Shimizu H, Matsuoka M, Soma T, et al
    Clinical Outcomes and Surgical Procedures for Patients With Osteosarcoma and Metachronous Lung Metastasis: A Chronological Analysis.
    J Surg Oncol. 2026;133:210-216.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

31. ORTIZ BA, Engrav SK, Boland JM, Roden AC, et al
    Diagnostic yield of routine frozen section pathology examination of lymph nodes in lung resections for clinical stage IA non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026;171:493-499.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

32. PECCI F, Agrawal P, Ross JS, Ricciuti B, et al
    Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
    J Thorac Oncol. 2026;21:310-317.
    PubMed         Abstract available
    
    
33. MINO-KENUDSON M, Berezowska S, Minami Y, Chen S, et al
    A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee.
    J Thorac Oncol. 2026;21:294-309.
    PubMed         Abstract available
    
    
34. LE X, Baik C, Cho BC, Riess JW, et al
    Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
    J Thorac Oncol. 2026;21:318-327.
    PubMed         Abstract available
    
    
35. DI FRISCO M, Sanmamed MF, Ferrandez JM, Vilalta A, et al
    Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2026;21:328-333.
    PubMed         Abstract available
    
    
36. MANKUZHY NP, Santo V, Shin JY, Chaunzwa TL, et al
    Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy.
    J Thorac Oncol. 2026 Jan 29:103565. doi: 10.1016/j.jtho.2026.103565.
    PubMed         Abstract available
    
    
37. NOVELLO S, Cheng Y, Spigel D, Fang J, et al
    Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial.
    J Thorac Oncol. 2026 Jan 30:103564. doi: 10.1016/j.jtho.2026.103564.
    PubMed         Abstract available
    
    
38. AL-KHAFAJI ASK, Al-Alloosh F, Alabedi HH, Al-Obaidi KMA, et al
    Lung Cancer in Iraq.
    J Thorac Oncol. 2026;21:227-234.
    PubMed        
    
    
39. LAM S, Baldwin DR, Devaraj A, Field J, et al
    A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening.
    J Thorac Oncol. 2026;21:235-252.
    PubMed         Abstract available
    
    
40. VAN MEERBEECK JP, Bousema JE, Wen W, Van Schil PEY, et al
    Staging of Lung Cancer: A Call for Developing Uniform and Universal Key Performance Indicators and Benchmarks to Elevate Clinical Standards.
    J Thorac Oncol. 2026;21:253-257.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

41. DE RUYSSCHER D, Damen PJJ, Hendriks LEL, Saw SPL, et al
    Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment.
    Lancet Oncol. 2026;27:155-158.
    PubMed        
    
    

    
    Lung Cancer

42. BOWEN JONES S, Gurumurthy G, Hayton C, Lodhi A, et al
    Corrigendum to "Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre" [Lung Cancer 211 (2026) 108873.
    Lung Cancer. 2026 Jan 29:108942. doi: 10.1016/j.lungcan.2026.108942.
    PubMed        
    
    

    
    Nat Med

43. HUANG Z, Zeng L, Ruan Z, Zeng Q, et al
    Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2026 Feb 2. doi: 10.1038/s41591-025-04181.
    PubMed         Abstract available
    
    

    
    Oncogene

44. REN YZ, Zhao MN, Du FL, Wu L, et al
    POM121 O-GlcNAcylation facilitates bone metastasis in non-small cell lung cancer through enhanced c-MYC nuclear import and ECM reprogramming.
    Oncogene. 2026 Feb 2. doi: 10.1038/s41388-026-03687.
    PubMed         Abstract available
    
    

    
    Oncol Rep

45. KOBAYASHI M, Konno C, Shimizu A, Kobayashi M, et al
    Tumor?associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid?derived suppressor cells and promotes antitumor immunity in triple?negative breast cancer?bearing mice.
    Oncol Rep. 2026;55:60.
    PubMed         Abstract available
    
    
46. JIN S, Zhang D, Liao Z, Yu L, et al
    TRIM46 deficiency?induced DNA damage enhances the sensitivity of cisplatin in non?small cell lung cancer by regulating the Akt signaling pathway.
    Oncol Rep. 2026;55:58.
    PubMed         Abstract available
    
    

    
    PLoS One

47. WEN H, Luo X, Zhong B, Xiao Y, et al
    MLND-IU: A multi-stage detection model of subcentimeter lung nodule with improved U-Net+.
    PLoS One. 2026;21:e0341750.
    PubMed         Abstract available
    
    
48. DE-LA-PUENTE-OVEJERO L, Fernandez-Rodriguez A, Francoz S, Aizpurua G, et al
    RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
    PLoS One. 2026;21:e0341778.
    PubMed         Abstract available
    
    
49. SHAH SNA, Issar K, Parveen R
    A hybrid feature extraction framework combining PCA and mutual information for gene expression based lung cancer classification.
    PLoS One. 2026;21:e0342160.
    PubMed         Abstract available
    
    
50. QIN S, Zhou S, Liu Y, Su D, et al
    Intratumoral spatial heterogeneity at non-contrast CT predicts histological grading of invasive pulmonary adenocarcinoma: a multicenter retrospective study.
    PLoS One. 2026;21:e0341163.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

51. TENDLER S, De Gregorio R, Balderes P, Michel AL, et al
    Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.
    Proc Natl Acad Sci U S A. 2026;123:e2505785123.
    PubMed         Abstract available
    
    

    
    Thorax

52. REZAEIANZADEH R, Sadatsafavi M
    Getting more than early detection from lung cancer screening.
    Thorax. 2026 Feb 5:thorax-2025-224617. doi: 10.1136/thorax-2025-224617.
    PubMed        
    
    
53. KIM SY, Kim YW
    Beyond detection: what happens after lung cancer screening matters more.
    Thorax. 2026 Feb 5:thorax-2025-224632. doi: 10.1136/thorax-2025-224632.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum